Day: November 15, 2021

Team Led by Experienced Fund Placement Professionals to Leverage Oppenheimer’s Scale, Thought Leadership and Resources to Further Deepen Service Offerings for Alternative Investment Firms

Expanded Service Offerings Expected to Drive Incremental Investment Banking & Capital Markets Opportunities in Technology & Healthcare, Real Assets-Focused Industries and Others

NEW YORK, Nov. 15, 2021 /PRNewswire/ — Oppenheimer & Co. Inc. (“Oppenheimer”) – a leading investment bank, wealth manager, and a subsidiary of Oppenheimer Holdings (NYSE: OPY) – today announced the launch of its new Global Fund Placement and Advisory Group (“FPA Group”). The FPA Group will provide services to leading alternative investment firms to help them fulfil their fundraising ambitions and strategic plans. Services will include strategic and tactical advice as well as fundraising services, both for primary funds and transactions.

Robert Lowenthal, Oppenheimer’s Senior Managing Director and Head of Investment Banking, said, “The Investment Banking Division is expanding its efforts around private capital formation with a focus on institutional private market investors. The FPA Group will provide the Division with enhanced capabilities to offer alternative investment firms an even broader and deeper portfolio of value-added services that complements the resources, relationships and thought leadership of the global Oppenheimer platform. The service the FPA group will provide includes a specialized level of expertise in advising global alternative investment firms. We are excited to launch this new Group as we establish a greater presence in the rapidly-growing global fundraising market.”

The Global Fund Placement and Advisory Group will be led by Tanya McHale, Managing Director, who will be based in London. Ms. McHale will report to Mr. Lowenthal, Head of Investment Banking in North America, and Max Lami, Oppenheimer EMEA Chief Executive and Head of Investment Banking.

Ms. McHale will be joined by Managing Director Andrew Roberts, Director Marcus Klasse and Associate Curran Gaur, who all join Oppenheimer from MVision Private Equity Advisers (“MVision”), a widely-respected independent international alternative assets advisory firm. The team will operate globally with further hires in process in the US and Asia.

Max Lami said, “It is a pleasure to welcome Tanya and the team to Oppenheimer. This team brings over 30 years of combined experience in successfully advising alternative investment firms and raising private equity funds. This talented and entrepreneurial group brings a proven track record of developing long-term relationships with private equity firms and institutional investors on a global basis. Adding this new dimension to our service platform is an important step toward strengthening our private capital markets business and will provide powerful growth opportunities for many of our clients.”

Prior to joining Oppenheimer, Ms. McHale served as a Managing Director at MVision, which she first joined at its founding in 2001. At MVision, Ms. McHale was a member of the firm’s leadership team and played a prominent role in global origination, execution and strategic advisory work for leading alternative investment firms, as well as distribution to institutional investors. Prior to MVision, she held positions at Credit Suisse First Boston and DLJ in London.

At MVision, Mr. Roberts played a leading role in origination, fundraising execution and strategic advisory work, as well as distribution, with a focus on investors in the UK and DACH region. Prior to MVision, Mr. Roberts worked at Cebile Capital in London for five years. Mr. Klasse spent five years at MVision, working on a number of leading fundraisings in EMEA as well as distribution, with a focus on investors in the Nordic region. Mr. Gaur focused on origination and research during his four years at MVision, as well as distribution to investors in the UK and Gulf Cooperation Council.

Ms. McHale said, “With Oppenheimer’s depth of expertise, global scale and prominent relationships, our new FPA Group will be ideally positioned to play a leading role in the global funds placement market. On behalf of my team, we are very pleased to be joining such a strong international platform, and we are excited about the synergies the FPA Group can bring to complement the services already offered by Oppenheimer while contributing to its further growth and success.”

Oppenheimer & Co. Inc.
Oppenheimer & Co. Inc. Oppenheimer & Co. Inc. (Oppenheimer), a principal subsidiary of Oppenheimer Holdings Inc. (OPY on the New York Stock Exchange), and its affiliates provide a full range of wealth management, securities brokerage and investment banking services to high net-worth individuals, families, corporate executives, local governments, businesses and institutions.

Media Contacts:
Joseph Kuo / Chris Clemens
Haven Tower Group
424 317 4851 or 424 317 4854
jkuo@haventower.com or cclemens@haventower.com

BAODING, China and MELBOURNE, Australia, Nov. 15, 2021 /PRNewswire/ — In Melbourne on 12th November, Australasia’s independent vehicle safety authority, A-NCAP SAFETY, announced a 5 star A-NCAP safety rating for all GWM Ute dual cab utilities built from 1 August 2021. The Ute has been assessed against A-NCAP’s current and most stringent 2020-2022 test criteria, providing a high level of safety to occupants and other road users. The GWM Pickup (also known as POER, P-Series, Cannon Ute) becomes the third vehicle in its segment to achieve 5 stars under the latest protocols.

GWM pickup performed well in A-NCAP testing, achieving full points in side impact and far-side impact tests (for both adult and child occupants), full points in testing of active lane support system functionality, strong scores for driver protection in frontal impact crashes, and a high level of protection in rear impact whiplash crashes.

“GWM has shown its dedication and commitment to providing its customers with the highest levels of safety by swiftly incorporating improvements to its pickup models, and its global consumers are being supplied with a safer vehicle,” said one GWM spokesman.

“Australia A-NCAP has a very mature assessment system and is one of the most stringent safety certification authorities in the world. In 2020, the A-NCAP standard has been upgraded and revised again just after 2 years aligned with ENCAP standards, and it is most stringent standard ever in history. We appreciate the engineering efforts done by GWM R&D team and are happy to see that with the concept of ‘smart safety’ in mind, GWM pickup particularly performed well in terms of ADAS features test items such as SAS, AEB, LDW, LKA have been added across the range,” Charles Zhao, MD of the GWM Australia added.

As one of the three major pickup markets in the world, Australia is a cultural mecca for lifestyle pickup lovers. Whether it is in the sparsely populated outback in Australia, or the great ocean road stretching for thousands of kilometers, off-road lovers can always find their favorite place here. Recognition from Australasian consumers are a solid proof for the quality of the GWM pickup.

Since it was launched in overseas market, GWM pickup has always put safety in the first place, especially its outstanding performance in the smart safety. It shows the unremitting efforts of GWM in automotive future direction and its firm direction in safety improvement. In the future, GWM Ute will continue to lead the development of pickup in the world with the industry’s benchmark in technological innovation.

Photo – https://mma.prnewswire.com/media/1687871/GWM.jpg

NANJING, China, Nov. 15, 2021 /PRNewswire/ — On November 15, 2021, Nanjing Vazyme Biotech Co., Ltd. (Vazyme) went public on the STAR MARKET of the Shanghai Stock Exchange under the stock code 688105.

Founded in Nanjing in 2012, Vazyme develops technologies and products related to functional proteins including enzymes, antigens and antibodies as well as organic polymer materials. Relying on its proprietary critical generic technology platform, the company has successively entered business areas including biological research, in vitro diagnosis and biomedicine. Vazyme is one of the few innovative R&D companies with both independent and controllable upstream technology development and final product manufacturing capabilities in China. The company owns more than 200 kinds of genetic engineering recombinases and 1,000 kinds of high-performance antigens and monoclonal antibodies. In addition, Vazyme has over 500 final products that have wide applications in scientific research, high-throughput sequencing, in vitro diagnosis, pharmaceutical and vaccine development as well as animal quarantine, among other fields.

Backed by many years of experience in the molecular biological reagent segment, Vazyme has strong R&D and product iteration capabilities, a perfected technical system and a well-established marketing network. Looking ahead, the publicly-listed company plans to accelerate its roadmap for an expanded presence in global markets, with the expectation of contributing to the ongoing development of the world’s biotechnology sector.

At the ceremony celebrating the firm’s success at listing on the Shanghai Stock Exchange, Vazyme chairman and founder Cao Lin said, “Today’s listing is of great significance to Vazyme. We have worked on obtaining this listing for nearly 10 years, in this period we made our full efforts and experienced all kinds of hardships. Vazyme will strictly comply with each and every one of the requirements and rules for listed companies, constantly enhance our management, communicate regularly with investors and maintain the transparency of our company, as part of our mission to give back to society and the shareholders by way of sustained growth and better performance.”

Photo – https://mma.prnewswire.com/media/1688018/image.jpg